CIK 0001835579 · <br>Emerging growth company
ImageneBio, Inc.
Sign in to watch- Ticker
- IMA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811697316
- Phone
- 857-343-8292
- Business address
- 12526 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
- Former names
- Ikena Oncology, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-25 | Marango Jotin CFO & Head of Corp. Dev. | Grant or award · Stock Option (Right to Buy) | +397,199 | 397,199 | ||
| 2022-02-03 | Manfredi Mark President & CEO | Grant or award · Stock Option (Right to Buy) | +238,900 | 238,900 | ||
| 2022-02-02 | Zhang Xiaoyan Michelle Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2022-02-02 | Santillana Sergio L. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +70,400 | 70,400 | ||
| 2022-02-02 | Ecsedy Jeffrey Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +59,360 | 59,360 | ||
| 2022-02-02 | Tessier Maude Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2022-01-21 | Wooster Richard Director | Grant or award · Stock Option (Right to Buy) | +29,200 | 29,200 | ||
| 2022-01-18 | Tessier Maude Chief Business Officer | Option exercise | +38,915 | $2.94 | $114K | 67,707 |
| 2022-01-18 | Tessier Maude Chief Business Officer | Option exercise | +24,606 | $4.15 | $102K | 92,313 |
| 2022-01-18 | Tessier Maude Chief Business Officer | Option exercise | +8,265 | $4.51 | $37K | 100,578 |
| 2022-01-18 | Tessier Maude Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −38,915 | 5,560 | ||
| 2022-01-18 | Tessier Maude Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −24,606 | 11,186 | ||
| 2022-01-18 | Tessier Maude Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −8,265 | 28,963 | ||
| 2022-01-11 | Zhang Xiaoyan Michelle Chief Scientific Officer | Option exercise | +964 | $2.15 | $2K | 45,439 |
| 2022-01-11 | Zhang Xiaoyan Michelle Chief Scientific Officer | Sale | −964 | $12.00 | $12K | 44,475 |
| 2022-01-11 | Zhang Xiaoyan Michelle Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −964 | 24,473 | ||
| 2022-01-10 | Zhang Xiaoyan Michelle Chief Scientific Officer | Option exercise | +36 | $2.15 | $77 | 44,511 |
| 2022-01-10 | Zhang Xiaoyan Michelle Chief Scientific Officer | Sale | −36 | $12.00 | $432 | 44,475 |
| 2022-01-10 | Zhang Xiaoyan Michelle Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −36 | 25,437 | ||
| 2021-12-21 | Koehler Maria Director | Grant or award · Stock Option (Right to Buy) | +13,419 | 13,419 |
Page 6 of 12 · 222 trades